Abstract:Introduction Intranasal esketamine has been approved as a treatment for patients with treatment-resistant depression. We analyzed the results of its efficacy in 15 patients. Objectives To evaluate the efficacy of intranasal Esketamine as a treatment in patients with treatment-resistant depression Methods Case series Results For the last 8 months, since the treatment with intranasal esketamine was approved for resistant depression, we have treated 14 patients with this drug. Through this process, we followed a standardized method consisting in the following steps: On the first esketamine session (DAY 1) the patient has to fill a CGI and a MADRS scale. On the second esketamine session (DAY 7) the patient has to fill a CGI, a MADRS scale, a form about the level of satisfaction with the drug and a last form in which they can include the secondary effects. On week 6 since the start of the treatment, the patient has to fill again a CGI, a MADRS scale, a form about the level of satisfaction with the drug and a last form in which they can include the secondary effects. In the 6th month since the start of the treatment, the patient has to fill again a CGI, a MADRS scale, a form about the level of satisfaction with the drug and a last form in which they can include the secondary effects they have perceived. We analyzed and compared all of the previous data and obtained the following results: At day 7: 64% of the patients had a response in the form of improvement, of which 66% were feeling "slightly better" and 33% were feeling "better". At week 6: 71% of the patients had a response in the form of improvement, of which 50% were feeling "slightly better" and the other 50% were feeling "better". At month 6: only 28% of the patients completed the treatment; of which 100% had a response in the form of improvement: 50% were feeling "slightly better", 25% were feeling "better" and 25% were feeling "far better". Conclusions Although our data suggests that intranasal esketamine has been effective in short term depressive symptoms, we have yet no information about its medium and long-term efficacy or secondary effects. Nevertheless, other potential factors should be evaluated as they could affect the results in the long-term such as the difficulty in maintaining the treatment for more than 6 weeks. In addition, the patients who experienced the most improvement according to our data were patients with a TAB diagnosis, so this could be an interesting research focus. Disclosure of Interest None Declared

Hypersomnia as a predictor of response to intravenous ketamine/intranasal esketamine in treatment resistant depression

Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression

Functional changes in sleep-related arousal after ketamine administration in individuals with treatment-resistant depression

Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study

Personalized use of ketamine and esketamine for treatment-resistant depression

Association Between Depression Subtypes and Response to Repeated-Dose Intravenous Ketamine

Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study

Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review

Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression

IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression

Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine

Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration

Esketamine rapid antidepression combined with dexmedetomidine sleep modulation for patients with depression and insomnia

Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants

Esketamine in depression: putative biomarkers from clinical research

Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity

Identifying Ketamine Responses in Treatment-Resistant Depression Using a Wearable Forehead EEG

The role of intranasal esketamine in treatment-resistant depression

Intranasal esketamine efficacy as a treatment for treatment-resistant depression, case series